Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel

PURPOSE: This pilot study aimed on generating insight on alterations in circulating immune cells during the use of FOLFIRINOX and gemcitabine/nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Peripheral blood mononuclear cells were isolated before and 30 days after ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Sams, L., Kruger, S., Heinemann, V., Bararia, D., Haebe, S., Alig, S., Haas, M., Zhang, D., Westphalen, C. B., Ormanns, S., Metzger, P., Werner, J., Weigert, O., von Bergwelt-Baildon, M., Rataj, F., Kobold, S., Boeck, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Brief Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455387/
https://www.ncbi.nlm.nih.gov/pubmed/33876417
http://dx.doi.org/10.1007/s12094-021-02620-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455387/
https://www.ncbi.nlm.nih.gov/pubmed/33876417
http://dx.doi.org/10.1007/s12094-021-02620-x

Ejemplares similares